Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Beijer Byggmaterial in connection with the acquisition of Kakeldax
Mandate

Vinge advises Beijer Byggmaterial in connection with the acquisition of Kakeldax

September 07, 2021 Employment and Benefits M&A Real Estate and Construction Corporate Commercial Intellectual Property

Vinge has advised Beijer Byggmaterial AB in connection with the acquisition of the Kakeldax group. The Kakeldax group consists of three strong brands – Stigs Kakel, Kakeldax and Kakelcentralen.

The group has more than 30 years of industry experience with 11 own stores, web shops and distributors across the country. The head office and central storage facility are located in Gothenburg.

Vinge’s team consisted of, among others, Jonas Bergström, Joacim Rydergård, Vilhelm Rondahl, Ellinor Wargenbrant and Beatrice Randow (M&A), Hedvig Ekdahl (Corporate Commercial), Frida Ställborn (Real Property/Lease Agreements), Lina Österberg (Environment), Karl-Hugo Engdahl (GDPR), Ebba Svenburg and Elin Broman (Employment Law), Felizia Wiker (IP) and Nathalie Hughes (VDR).

 

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025